Document Detail


Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.
MedLine Citation:
PMID:  23211088     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite advances in rheumatoid arthritis (RA) treatment, efficacious and safe disease-modifying therapy still represents an unmet medical need. Here, we describe an innovative strategy to treat RA by targeting low doses of vasoactive intestinal peptide (VIP) self-associated with sterically stabilized micelles (SSMs). This spontaneous interaction of VIP with SSM protects the peptide from degradation or inactivation in biological fluids and prolongs circulation half-life. Treatment with targeted low doses of nanosized SSM-VIP but not free VIP in buffer significantly reduced the incidence and severity of arthritis in an experimental model, completely abrogating joint swelling and destruction of cartilage and bone. In addition, SSM associated VIP, unlike free VIP, had no side-effects on the systemic functions due to selective targeting to inflamed joints. Finally, low doses of VIP in SSM successfully downregulated both inflammatory and autoimmune components of RA. Collectively, our data clearly indicate that VIP-SSM should be developed to be used as a novel nanomedicine for the treatment of RA.
Authors:
Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Related Documents :
23295698 - Topical therapy.
16517528 - Tetracycline residues in honey after hive treatment.
24804178 - Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne.
10549458 - Milrinone enhances the contractility of fatigued diaphragm in dogs: a dose-ranging study.
215808 - Effect of dimercaptosuccinic acid on toxicity of habu snake (trimeresurus flavoviridis,...
16381778 - Orange, a new, fast dose engine for radiotherapy treatment planning.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2013-01-23
Journal Detail:
Title:  Molecular pharmaceutics     Volume:  10     ISSN:  1543-8392     ISO Abbreviation:  Mol. Pharm.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-04     Completed Date:  2013-08-20     Revised Date:  2014-02-05    
Medline Journal Info:
Nlm Unique ID:  101197791     Medline TA:  Mol Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  728-38     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Arthritis, Rheumatoid / drug therapy*
Inflammation / drug therapy
Male
Mice
Micelles*
Nanomedicine
Phospholipids / chemistry
Vasoactive Intestinal Peptide / chemistry,  therapeutic use*
Grant Support
ID/Acronym/Agency:
AG024026/AG/NIA NIH HHS; C06RR15482/RR/NCRR NIH HHS; CA121797/CA/NCI NIH HHS; HL72343/HL/NHLBI NIH HHS; R01 AG024026/AG/NIA NIH HHS; R01 CA121797/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Micelles; 0/Phospholipids; 37221-79-7/Vasoactive Intestinal Peptide
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Lagrangian level set-like method for modelling and simulation in bioengineering.
Next Document:  Disease activity and cognition in rheumatoid arthritis: an open label pilot study.